FDA approves tisotumab vedotin-tftv for recurrent or metastatic cervical cancer

30 Apr 2024
FDA approves tisotumab vedotin-tftv for recurrent or metastatic cervical cancer

On April 29, 2024, the Food and Drug Administration granted traditional approval to tisotumab vedotin-tftv for recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. Tisotumab vedotin-tftv previously received accelerated approval for this indication.

Full prescribing information for tisotumab vedotin-tftv will be posted here.

Efficacy and Safety

Efficacy was evaluated in innovaTV 301 (NCT04697628), an open-label, active-controlled, multicenter, randomised trial that enrolled 502 patients with recurrent or metastatic cervical cancer who had received one or two prior systemic regimens, including chemotherapy with or without bevacizumab and/or an anti-PD-(L)-1 agent. Patients were excluded if they had active ocular surface disease, any prior episode of cicatricial conjunctivitis or ocular Stevens-Johnson syndrome, Grade ≥2 peripheral neuropathy, or clinically significant bleeding issues or risks.

Patients were randomised (1:1) to receive either tisotumab vedotin 2 mg/kg intravenously every 3 weeks or investigator’s choice of chemotherapy consisting of topotecan, vinorelbine, gemcitabine, irinotecan, or pemetrexed, until unacceptable toxicity or disease progression.

The major efficacy outcome measure was overall survival (OS). Additional efficacy outcome measures were progression free survival (PFS) and confirmed objective response rate (ORR) as assessed by the investigator using RECIST v1.1. Median OS was 11.5 months (95% CI: 9.8, 14.9) in the tisotumab vedotin arm and 9.5 months (95% CI: 7.9, 10.7) in the chemotherapy arm (Hazard Ratio [HR] 0.70 [95% CI: 0.54, 0.89] p-value 0.0038). Median PFS was 4.2 months (95% CI: 4.0, 4.4) in the tisotumab vedotin arm and 2.9 months (95% CI: 2.6, 3.1) for those treated with chemotherapy (HR 0.67 [95% CI: 0.54, 0.82] p-value <0.0001). Confirmed ORR was 17.8% (95% CI: 13.3, 23.1) and 5.2% (95% CI: 2.8, 8.8) in the respective arms (p-value <0.0001). This trial’s results fulfill the post-marketing requirement of the previous accelerated approval.

The most common adverse reactions (≥25%), including laboratory abnormalities, were decreased haemoglobin, peripheral neuropathy, conjunctival adverse reactions, increased aspartate aminotransferase, nausea, increased alanine aminotransferase, fatigue, decreased sodium, epistaxis, and constipation.

The recommended tisotumab vedotin dose is 2 mg/kg (maximum of 200 mg for patients ≥100 kg) administered as an intravenous infusion over 30 minutes every 3 weeks until disease progression or unacceptable toxicity.

Source: FDA